Thursday, March 7, 2013

UK men 'losers in European prostate cancer lottery'

Access to life-extending drugs for the disease, which kills 10,000 a year in the UK, is poorer than in France, Spain, Germany and Italy, according to the report, sponsored by the drugs firm Astellas.

Dr Heather Payne, a consultant oncologist at University College London Hospitals NHS Foundation Trust, said: “There are many reasons for international differences in cancer survival, but swift access to innovative treatments and the availability of best practice care are important in order to deliver the best outcomes in terms of life extension and quality of life.